Researchers at the University of Maryland School of Medicine (UMSOM) evaluated several human antibodies to determine the most potent combination to be mixed in a cocktail and used as a promising antiviral therapy against the virus that causes COVID-19.

For our comprehensive coverage and latest updates on COVID-19 click here.

Their research, conducted in collaboration with scientists at Regeneron Pharmaceuticals, was published today in the journal Science. The study demonstrates the rapid process of isolating, testing and mass-producing antibody therapies against any infectious disease by using both genetically engineered mice and plasma from recovered COVID-19 patients.

The antibody cocktail evaluated by UMSOM researchers will be used to treat COVID-19 patients in a clinical trial that was launched last week. The study was funded by Regeneron, a biotechnology company based in Tarrytown, NY.